213 related articles for article (PubMed ID: 36087226)
1. Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Umezawa Y; Sasaki K
Int J Hematol; 2023 Jan; 117(1):24-29. PubMed ID: 36087226
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system.
Malkan UY; Haznedaroglu IC
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5493-5506. PubMed ID: 37401285
[TBL] [Abstract][Full Text] [Related]
3. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
Haznedaroğlu İC; Kuzu I; İlhan O
Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Collins JB; Muluneh B; Profitt S
J Oncol Pharm Pract; 2024 Mar; 30(2):385-396. PubMed ID: 38105466
[TBL] [Abstract][Full Text] [Related]
5. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
Bhalla S; Tremblay D; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
[TBL] [Abstract][Full Text] [Related]
6. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
7. [Recognizing and managing side effects of tyrosine kinase inhibitors in chronic myeloid leukemia].
Dereme J; Ségot A; Friedrich N; Tsilimidos G; Blum S
Rev Med Suisse; 2023 Nov; 19(850):2175-2181. PubMed ID: 37966150
[TBL] [Abstract][Full Text] [Related]
8. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
Dou X; Qin Y; Huang X; Jiang Q
Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
[TBL] [Abstract][Full Text] [Related]
9. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Flynn KE; Myers JM; D'Souza A; Schiffer CA; Thompson JE; Atallah E
Oncologist; 2019 Sep; 24(9):1253-1258. PubMed ID: 30944185
[TBL] [Abstract][Full Text] [Related]
10. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
11. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
12. When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently.
Cerveira N; Bizarro S; Teixeira MR; Mariz JM
Curr Treat Options Oncol; 2021 Apr; 22(6):49. PubMed ID: 33866455
[TBL] [Abstract][Full Text] [Related]
13. [What is the best treatment for chronic-phase CML?].
Sakaida E
Rinsho Ketsueki; 2021; 62(8):1012-1023. PubMed ID: 34497187
[TBL] [Abstract][Full Text] [Related]
14. How to manage CML patients with comorbidities.
Cortes J
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):237-242. PubMed ID: 33275749
[TBL] [Abstract][Full Text] [Related]
15. [Novel therapies for chronic myeloid leukemia].
Iriyama N
Rinsho Ketsueki; 2022; 63(6):655-659. PubMed ID: 35831202
[TBL] [Abstract][Full Text] [Related]
16. [Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].
Miyazaki S
Rinsho Ketsueki; 2021; 62(8):1024-1028. PubMed ID: 34497188
[TBL] [Abstract][Full Text] [Related]
17. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
Lee H; Basso IN; Kim DDH
Int J Hematol; 2021 May; 113(5):632-641. PubMed ID: 33772728
[TBL] [Abstract][Full Text] [Related]
18. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
[TBL] [Abstract][Full Text] [Related]
19. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence.
Ciftciler R; Haznedaroglu IC
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):7787-7798. PubMed ID: 34982440
[TBL] [Abstract][Full Text] [Related]
20. How to manage CML patients with comorbidities.
Cortes J
Blood; 2020 Nov; 136(22):2507-2512. PubMed ID: 33236757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]